Should you buy Tekla Life Sciences Investors stock? (NYSE:HQL). Let's see how it does in our automated value investing analysis system.
Advantages | Disadvantages |
---|---|
|
|
HQL Price (Tekla Life Sciences Investors stock price per share) |
$14.72 | |
PE Ratio versus Sector | 78% lower than other Financial stocks | |
PE Ratio versus Industry | 83% lower than other Asset Management stocks | |
Free Cash Flow Jitter | 0% | |
Dividend Yield | 10% | Shares Shorted | 30,972 |
Based on our analysis, we believe that you should not buy Tekla Life Sciences Investors right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.
Does Tekla Life Sciences Investors have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles
How Does Portfolio Churning Affect Your Returns?
What are The Dow, S&P 500, and NASDAQ Indexes?
What Happened to the Stock Market Today?
What is Self-Directed Investing?
Should You Invest in Gold or Silver?
What is a Good Annual Rate of Return?
How Do Interest Rates Affect Stock Prices?